hengrui glp-1 China Challenges Leaders, ㅤ, Kailera licensed a portfolio of obesity therapies from China's Jiangsu Hengrui, including a Phase 3 GLP-1 candidate that delivered up to 10.9% average weight loss at Dealmakers push for next-generation obesity
Pay in 4 interest-free payments of $7.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6







:format(webp))













